Effective analgesia after midline laparotomy surgery is essential for enhanced recovery programs. We compared three types of continuous abdominal wall block for analgesia after midline laparotomy for gynaecological oncology surgery. We conducted a single-centre, double-blind randomised controlled trial. Ninety-four patients were randomised into three groups to receive two days of programmed intermittent boluses of ropivacaine (18 ml 0.5% ropivacaine every four hours) via either a transversus abdominis plane (TAP) catheter, posterior rectus sheath (PRS) catheter, or a subcutaneous (SC) catheter. All groups received patient-controlled analgesia with morphine, and regular paracetamol and non-steroidal anti-inflammatory medication. Measured outcomes included analgesic and antiemetic usage and visual analog scores for pain, nausea, vomiting, and satisfaction. Eighty-eight patients were analysed (29 SC, 29 PRS and 30 TAP). No differences in the primary outcome were found (median milligrams morphine usage on day two SC 28, PRS 25, TAP 21, P=0.371). There were differences in secondary outcomes. Compared with the SC group, the TAP group required less morphine in recovery (0 mg versus 6 mg, P=0.01) and reported less severe pain on day one (visual analog scores 36.3 mm versus 55 mm, P=0.04). The TAP group used fewer doses of tropisetron on day one compared with the PRS group (8 versus 21, P=0.016). Programmed intermittent boluses of ropivacaine delivered via PRS, TAP and SC catheters can be provided safely to patients undergoing midline laparotomy surgery. Initially TAP catheters appear superior, reducing early opioid and antiemetic requirements and severe pain, but these advantages are lost by day two.
Blockade of the spinal nerves innervating the abdominal wall is an essential component of multimodal analgesia to enhance recovery in patients undergoing major abdominal surgery.
The innervation of the abdominal wall is derived from the thoracolumbar spinal nerves from T6 to L1 and forms a neural plexus located in the transversus abdominis plane (TAP), between the transversus abdominis and internal oblique muscles. The plexus then travels through the semilunaris fascia and into the posterior rectus sheath (PRS). Here, the nerves pierce rectus abdominis and move anteriorly into the subcutaneous (SC) layer to supply the skin of the anterior abdominal wall. A complete study of the innervation of the anterior abdominal wall was made by Rozen et al in 2008 1 . Central neuraxial blockade with a low thoracic epidural delivers high quality analgesia for midline laparotomy surgery, but has a high failure rate on the postsurgical ward 2 . In addition, epidurals result in hypotension 3 and urinary catheter dependence, impede patient ambulation and, rarely, cause catastrophic neurological damage 4 . Peripheral nerve blockade by local anaesthetic (LA) deposition into the TAP, PRS or SC compartments may provide a safe and effective alternative to epidural analgesia.
These three peripheral block techniques (TAP, SC and PRS) in isolation can provide analgesic sparing after various abdominal surgeries [5] [6] [7] [8] [9] [10] [11] . There is a large heterogeneity in the trials investigating PRS, TAP and SC in terms of measured outcomes, types of surgery, block techniques, and anatomical positioning of block catheters 12, 13 . In addition many studies are of poor quality or have inconsistent conclusions 8, [14] [15] [16] . No published trials have directly compared these three techniques (PRS, TAP and SC). As a result, it is challenging to produce any useful clinical recommendations or guidelines on abdominal wall blocks. In theory, a technique targeting the costal nerves proximally would provide improved spread and depth of neural blockade 1 . Therefore, we devised a clinical study to investigate and compare two days of programmed intermittent boluses (PIB) of LA via SC, PRS and TAP catheters after midline laparotomy for major gynaecological oncology surgery.
Our hypothesis was that the PRS and TAP groups, which target the innervation of the abdominal wall, would be more opioid sparing compared with the SC group. We predicted that this effect would be most significant on the second postoperative day when patients mobilise and experience more somatic than visceral pain. Thus, our primary outcome was mean morphine consumption on day two.
Materials and methods

Ethics approval
The study was reviewed and approved by the Mater Health Services Human Research Ethics Committee (HREC 00332) and was conducted in accordance with the current national statements and codes of clinical research. The study was registered with the World Health Organization under the Universal Trial Number (UTN) U1111-1134-4069.
Study design
This was a single centre, double-blinded, randomised controlled trial performed at the Mater Adult and Mothers Hospital, Brisbane, between November 2012 and April 2015.
Study population
All patients undergoing midline laparotomy for gynaecological oncology surgery were eligible for enrolment. Patients were excluded if they were opioid dependent, obese (body mass index >35), had a contraindication to abdominal wall block (local sepsis, LA allergy, abnormal anatomy), preferred an alternative postoperative analgesia technique (epidural), required formation of a stoma, were aged less than 18 years, or had inadequate capacity to consent.
Conduct of the study
Full written informed consent was sought in patients who fulfilled the inclusion criteria and did not meet the exclusion criteria. Once obtained, patients were randomised into three groups using sealed envelopes labelled participant 1 to 94. The envelopes were prepared by an independent statistician using a computer-generated random sequence table for three groups. A numbered envelope was opened by an investigator after the commencement of surgery to reveal the participant's allocated group (SC, TAP or PRS). Patients, nursing staff and data collectors were blinded to group allocation.
Clinical management
All patients received a standardised volatile general anaesthetic without neuraxial anaesthesia. Patients received prophylactic antiemetics (tropisetron and metoclopramide), paracetamol and parecoxib (if not contraindicated). A dose of intraoperative intravenous (IV) morphine was administered at the discretion of the treating anaesthetist. In addition to this, IV morphine was provided in the post-anaesthetic care unit (PACU) by the recovery nurses in accordance with their pain protocol. The bilateral regional analgesia catheters were inserted at the end of surgery: the TAP by an anaesthetist, PRS by the surgeon, and the SC by an anaesthetist or surgeon (see below for the description of the insertion techniques). The catheter entry site and dressings were standardised in all groups. The catheters were joined together with a Y connector and an initial bolus of 40 ml 0.5% ropivacaine was administered. Eight hours after this initial bolus, automated four-hourly PIB were commenced by a programmed Gemstar © pump (Hospira, Lake Forest, IL, USA). Each bolus delivered 18 ml of 0.5% ropivacaine (540 mg ropivacaine per day). The PIB were ceased 48 hours after surgery. Postoperative analgesic management included an IV morphine patient-controlled analgesia system (1 mg bolus with five-minute lockout), regular paracetamol, and non-steroidal anti-inflammatory drug (NSAID), if not contraindicated. Patients were reviewed regularly by the pain team, who were blinded to group allocation. The pain service was able to administer additional analgesics if indicated. Antiemetics were available on patient request. Tropisetron was administered first, followed by metoclopramide if nausea or vomiting persisted.
Insertion techniques for the three treatment arms
TAP block catheter technique
Using full asepsis, a Sonosite © (SonoSite Australasia Pty Ltd, Belrose, New South Wales) M-Turbo® Ultrasound 38 mm linear array 13-6MHz probe was used to locate the abdominal wall muscles. A 20 cm 16G Eldor © Tuohy needle (product code CSEN194_2) was inserted in the middle of the upper abdominal quadrant in an inferolateral direction. Using ultrasound guidance, the needle was advanced under the lateral edge of the rectus, through the semilunaris fascia and into the TAP beneath the internal oblique muscle. Aqua dissection was used to separate the fascia. The Eldor surgical site catheter (with 10 cm of distal fenestrations) was inserted through the needle into this fascial pocket and secured at the skin between the 15 and 20 cm markers. This was repeated on the contralateral side. The TAP catheters were inserted by eight different anaesthetists after instruction by a researcher to ensure uniformity.
Posterior rectus sheath catheter technique
On abdominal wall closure, the PRS was grasped with a pair of Moynihan forceps or similar instrument. With a combination of sharp and blunt dissection, a space was created between the rectus abdominis muscle anteriorly and the rectus sheath posteriorly. Care was taken not to injure the inferior epigastric vessels. A 20 cm 16G Eldor Tuohy needle was passed through the skin in the middle of the upper abdominal quadrant into the surgically created fascial space. The Eldor catheter was inserted through the needle into this fascial pocket and secured at the skin between the 15 and 20 cm markers. This was repeated on the contralateral side. The anterior abdominal wall was closed in the usual fashion taking care not to incorporate the catheter into the closing suture. The PRS catheters were inserted by, or under the direct supervision of, the three gynae-oncology surgeons.
Subcutaneous catheter technique
Using full asepsis, the same type of Eldor needle was passed through the skin in the middle of the upper abdominal quadrant and advanced subcutaneously in an inferior direction parallel to the wound. Ultrasound guidance and aqua dissection was permitted if necessary. The Eldor catheter was inserted through the needle into the SC space and secured at the skin between the 15 and 20 cm markers. This was repeated on the contralateral side.
Data Collection
All data was collected prospectively on a specifically designed data collection sheet. Preoperative peak expiratory flow rates (PEFR), demographic and baseline operative data was recorded by the treating anaesthetist. A recovery nurse blinded to the randomisation was allowed to administer IV opioids in the PACU according to their standard pain protocol. Total PACU opioid requirements and time in PACU was noted. Two 'blinded' research pain nurses assessed patients on the gynae-oncology ward at approximately 24 and 48 hours postoperatively. At these times PEFR and visual analog scores (VAS) for pain, satisfaction, nausea, and vomiting were recorded. Opioid, antiemetic, and non-opioid analgesic usage, and length of hospital stay was also documented. If other opioids were used, then a total morphine dose was calculated using the Australian and New Zealand College of Anaesthetists Faculty of Pain Medicine opioid calculator 10 mg tramadol = 15 µg fentanyl = 1 mg morphine (http://fpm. anzca.edu.au/front-page-news/free-opioid-calculator-app).
Statistical analysis and power calculation
A power calculation was performed from morphine consumption data collected in 20 patients undergoing midline laparotomy for gynae-oncology surgery prior to the introduction of regional analgesia techniques. A postoperative day two mean morphine consumption of 56 mg with a standard deviation of 30 mg was calculated. Using a predicted 45% reduction of morphine consumption in the treatment groups (PRS & TAP) with a type I error of 0.05 and power of 80% we calculated that 22 patients would be necessary for each group. A reduction of morphine of less than 45% in the treatment group would have been deemed clinically insignificant. To allow for dropout and post hoc testing we decided to recruit at least 94 patients. Analysis of the data was performed by an independent statistician using Stata/SE 13.1 (Statacorp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA: STATACorp LP). The test for skewness was done by visual analysis of the distribution of the variables using histograms. Normally distributed data was analysed using one-way analysis of variance. Nonparametric data was analysed using the Kruskal-Wallis (Dunn's) test. A post hoc Bonferroni correction was used for multiple comparisons. Both the one-way analysis of variance and the Dunn's test incorporate post hoc Bonferroni adjusted P-values.
Results
A total of 143 patients were assessed for eligibility. Forty-nine patients did not meet the inclusion criteria or declined to participate. Ninety-four patients were recruited, randomised and consented. Six patients were excluded after randomisation due to protocol violations (two patients had unexpected admissions to intensive care, one patient had Table 2 displays the primary and secondary outcome data. There were no statistical differences in the primary outcome (median morphine consumption on day two). The median and interquartile range (IQR) for each group were SC 28 mg (13-57), PRS 25 mg (10-38) and TAP 21 mg (10-34) with P-value of 0.371.
There were statistical differences with some of the secondary outcome data. Compared with the SC group, the TAP group required less rescue morphine in PACU (administered as per the standardised pain protocol). The median and IQR for each group were SC 6 mg (0-10) versus TAP 0 mg (0-2) with a P-value of 0.01. Day one worst pain measured by VAS was less in the TAP group compared with the SC group. The mean and SD for each group was TAP 36.3 mm (29.2) versus SC 55 mm (24.9) with P-value 0.04. Less tropisetron was administered in the TAP group 
Discussion
In this single centre, double-blinded, randomised clinical study we showed no difference in median morphine consumption on the second postoperative day between the SC, PRS and TAP groups when using PIB of LA after midline laparotomy for gynaecological oncology surgery.
Although we found no differences in our primary outcome, patients in the TAP group required less opioids in PACU and had less severe pain on day one compared with the SC group. In addition, the TAP group used less antiemetic compared with the PRS group on day one. This suggests that for midline laparotomy, TAP targeted PIB of ropivacaine initially provide superior analgesia when compared to SC and PRS. These advantages did not extend into day two. No major complications were reported in any of the groups supporting the existing evidence that abdominal wall blocks are a safe alternative to epidural analgesia 17, 18 .
While there are no published comparisons of continuous TAP and PRS blocks, there are three randomised controlled trials comparing epidural analgesia with continuous TAP blocks. Two studies found continuous TAP blocks were equally effective as epidural analgesia; one after open abdominal surgery 19 and the other after laparoscopic bowel surgery 16 . However, the third reported that patients with low thoracic epidurals had less pain and required less analgesia when compared with patients with continuous TAP blocks after open abdominal surgery 20 .
Opioid requirements were significantly reduced in PACU in the TAP group compared with the SC group (median 0 mg versus 6 mg). This is consistent with published data investigating the analgesic-sparing effects of bilateral single shot TAP blocks after abdominal surgery 5 . Reduced patient opioid usage in PACU should lead to improved utilisation of PACU and cost savings. Disappointingly, our study did not show reduced PACU times in the TAP group patients.
There was also a trend towards less opioid usage in the TAP group on day one compared with the SC and PRS group (median 22.5 mg versus 31 mg and 32 mg). This non-statistical reduction in morphine consumption may be clinically significant as the TAP group required less tropisetron on day one compared with the PRS group.
We accept there are some limitations to our study. The power calculation was performed on data which was normally distributed. Unfortunately, our primary outcome data was not normally distributed, requiring non-parametric statistical analysis. This increases the likelihood of a type II error.
Due to an increasing amount of laparoscopic surgery at our institution, the trial took longer than anticipated. It was conducted over a three-year period, increasing the risk of confounding factors. However, there were no significant changes in the gynae-oncology surgical and anaesthetic teams or hospital policies over the duration of the trial. A comprehensive meta-analysis of wound catheters in 2011 concluded that SC wound catheters for abdominal surgery provide minimal analgesic benefit after abdominal surgery 12 . Therefore, we made the SC group our surrogate placebo. Our original study design included a true saline placebo group but this was deemed unethical by HREC as it would have put patients at unnecessary risk and denied them regional analgesia. This ethics decision has been supported by two recently published trials which compared continuous TAP and PRS blocks to saline placebo after gynae-oncology laparotomy surgery. Both showed TAP and PRS blockade reduced opioid requirements and pain compared with the saline placebo 10, 11 .
Clinical trials have established that IV and SC administration of lignocaine provides effective systemic analgesia 21 . As ropivacaine has an identical mode of action to lignocaine (sodium channel blockade) it is possible that systemic absorption of ropivacaine also has an analgesic effect. Studies have shown that after a single TAP injection of 200 mg ropivacaine, plasma ropivacaine levels often exceed 2.20 µg/ml 22, 23 . Research is required to establish whether systemic ropivacaine absorption contributes to the opioidsparing effects reported with abdominal wall regional anaesthesia. Due to limited resources, we did not measure serial serum ropivacaine levels and therefore we cannot comment on the potential analgesic effect of systemic ropivacaine.
No clinical features of LA toxicity were reported in the duration of our trial.
Finally, our TAP catheters were inserted by six different anaesthetists. Although we accept this may have resulted in an increased variation in catheter insertion technique it does reflect real anaesthetic practice.
Even with the continuous abdominal wall regional anaesthesia we observed that the majority of patients from all the study groups still reported mild to moderate pain and nausea. Further research is essential to investigate refinements and improvements in these analgesic techniques to improve patient outcomes. Despite this, nearly all our patients were highly satisfied with the care they received at the Mater Hospital.
Conclusion
Our study supports the growing body of evidence that continuous abdominal wall catheters may provide safe and effective analgesia for midline laparotomy surgery. Initially TAP targeted local anaesthetic infusions appear to be superior when compared with PRS and SC ones. However, these early opioid-and antiemetic-sparing effects are lost by day two.
